Overview

Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Decitabine may help myelodysplastic cells become more like normal stem cells. PURPOSE: This clinical trial studies differentiation therapy with decitabine in treating patients with myelodysplastic syndrome.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Case Comprehensive Cancer Center
Treatments:
Azacitidine
Decitabine